OraSure Technologies, Inc.(OSUR)- NASDAQ
  • Fri, Sep. 23, 8:28 AM
    • Clovis Oncology (NASDAQ:CLVS) upgraded to Outperform from Neutral by Credit Suisse. Price target raised to $41 (7% upside) from $19.
    • Sarepta Therapeutics (NASDAQ:SRPT) upgraded to Outperform from Market Perform with a $64 (5% upside) price target by Cowen and Company. Upgraded to Hold from Underperform with a $50 (18% downside risk) price target by Jefferies. Upgraded to Outperform from Market Perform with an $88 (44% upside) price target by William Blair. Upgraded to Neutral from Reduce by SunTrust Banks. Price target raised to $48 (21% downside risk) from $4. Upgraded to Market Perform from Underperform with a $50 (18% downside risk) price target by Leerink Swann. Upgraded to Buy from Neutral by Janney Montgomery Scott. Price target raised to $65 (7% upside) from $30.
    • Molina Healthcare (NYSE:MOH) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $58 (2% downside risk) from $51.
    • Tobira Therapeutics (NASDAQ:TBRA) downgraded to Hold from Buy by Cantor Fitzgerald. Price target raised to $42 (6% upside) from $19.
    • OraSure Technologies (NASDAQ:OSUR) downgraded to Neutral from Buy by BTIG Research. $8 price target removed.
    | Fri, Sep. 23, 8:28 AM | 3 Comments
  • Tue, Sep. 13, 2:49 AM
    • After meeting with the top four congressional leaders on Monday, President Obama said he was encouraged that lawmakers would be able to reach an agreement on funding to fight the Zika virus.
    • In February, Obama had asked Congress to approve $1.9B in emergency funds to battle Zika with diagnostic tools and vaccines, but disagreements over side issues related to abortion led to divisions about full funding.
    • Related tickers: SNY, ABT, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX, OSUR
    | Tue, Sep. 13, 2:49 AM | 19 Comments
  • Fri, Sep. 9, 5:34 AM
    • Pre-dawn aerial spraying for Zika-carrying mosquitoes has begun in Miami Beach, but it's bugging out some locals due to health concerns surrounding insecticide Naled.
    • Originally scheduled for Thursday, the spraying was delayed for a day after angry residents protested.
    • So far there have been 56 locally transmitted and 596 travel-related Zika cases in Florida. According to the CDC, there are 2,977 cases of the virus in the continental U.S.
    • Related tickers: SNY, ABT, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX, OSUR
    | Fri, Sep. 9, 5:34 AM | 40 Comments
  • Sun, Aug. 28, 12:52 PM
    • Singapore authorities have identified 41 Zika cases that were transmitted locally, and warned that they expect to find more.
    • The cases appear to be the largest single beachhead the virus has made in Asia in the current epidemic, which has also been detected in countries like Bangladesh, Malaysia and the Philippines.
    • On Thursday, China added the U.S. to a list of Zika-infected countries, worrying U.S. exporters, who fear they will be required to fumigate containers destined for Chinese ports.
    • Related tickers: SNY, ABT, INO, AEMD, XON, CEMI, BCRX, TMO, OTCQB:GOVX, OSUR
    | Sun, Aug. 28, 12:52 PM | 18 Comments
  • Fri, Aug. 26, 11:01 AM
    • The FDA revises its guidance on screening whole blood and blood components for the Zika virus. It now recommends all U.S. states and territories implement testing to ensure the safety of the blood supply. Collection/processing centers can use either an investigational test authorized by the FDA under an IND or a licensed test when available.
    • In February, the agency recommended the safety measure only in areas with active Zika virus transmission. All such areas (i.e., FL and Puerto Rico) are now in compliance with the guidance.
    • Related tickers: (NASDAQ:CEMI)(NASDAQ:OSUR)(NYSE:SNY)(NYSE:ABT)(NASDAQ:AEMD)(NYSE:TMO)(OTCQX:RHHBY)(OTCPK:SIEGY)
    | Fri, Aug. 26, 11:01 AM | 1 Comment
  • Wed, Aug. 24, 12:48 PM
    | Wed, Aug. 24, 12:48 PM
  • Wed, Aug. 24, 11:02 AM
    | Wed, Aug. 24, 11:02 AM
  • Wed, Aug. 24, 9:14 AM
    | Wed, Aug. 24, 9:14 AM | 2 Comments
  • Tue, Aug. 23, 5:40 PM
    • OraSure Technologies (NASDAQ:OSUR+9.8% AH on news that it was awarded a contract for as much as $16.6M from the U.S. Department of Health and Human Services to accelerate development of its oral test kits for the Zika virus.
    • OSUR says its rapid Zika tests will be superior to the examination of tissue or blood samples because the virus can be detected earlier with its technique.
    • According to the U.S. Centers for Disease Control and Prevention, as of Aug. 11 there were 529 cases of pregnant women possibly infected with the Zika virus.
    | Tue, Aug. 23, 5:40 PM | 3 Comments
  • Tue, Aug. 23, 5:35 PM
    • Top gainers, as of 5.25 p.m.: LCI +14.7%. OSUR +9.3%. TEF +6.6%. UAN +2.0%. CLVS +2.9%.
    • Top losers, as of 5.25p.m.: LZB -14.6%. DY -4.2%. INTU -3.9%. ANET -2.6%. AER -2.3%.
    | Tue, Aug. 23, 5:35 PM
  • Wed, Aug. 3, 4:21 PM
    • OraSure Technologies (NASDAQ:OSUR): Q2 EPS of $0.07 beats by $0.02.
    • Revenue of $31.36M (+3.2% Y/Y) beats by $0.21M.
    • Press Release
    | Wed, Aug. 3, 4:21 PM
  • Tue, Aug. 2, 5:35 PM
  • Fri, Jul. 1, 7:07 AM
    • Micro cap OraSure Technologies (NASDAQ:OSUR) fell 16% yesterday on more than 8x normal volume as informed investors ran for the exits before today's announcement that AbbVie (NYSE:ABBV) has backed out of its co-promotion agreement regarding OraSure's OraQuick HCV Rapid Antibody Test. The deal will now end on December 31 of this year instead of December 31, 2019.
    • OraSure was supposed to receive up to $75M in exclusivity payments from AbbVie over the term of the partnership. It has been ratably recognizing the payments since the deal was inked in June 2014 and will book $5.4M for the remainder of this year.
    • When the agreement ends, AbbVie will have no further obligations to co-promote the test or any other obligations to OraSure.
    • OraSure will host a conference call this morning at 8:30 am ET to discuss the situation. Shares are down 11% premarket this morning.
    • SA Contributor Richard Pearson nailed the call: Expect OraSure To Drop 35% (Or More) Next Week
    | Fri, Jul. 1, 7:07 AM | 4 Comments
  • Thu, Jun. 30, 12:46 PM
    | Thu, Jun. 30, 12:46 PM | 8 Comments
  • Thu, Jun. 30, 11:00 AM
    | Thu, Jun. 30, 11:00 AM
  • Fri, Jun. 17, 7:06 AM
    • Hill Rom Holdings (NYSE:HRC) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $62 (20% upside) from $54.
    • Arbutus Biopharma (NASDAQ:ABUS) upgraded to Neutral from Sell by Chardan. Price target is $3.25 (1% downside risk).
    • Achaogen (NASDAQ:AKAO) upgraded to Outperform from Neutral by Wedbush. Price target raised to $10 (111% upside) from $7.
    • PRA Health Sciences (NASDAQ:PRAH) upgraded to Overweight from Sector Weight by KeyBanc. Price target is $55 (25% upside).
    • Agios Pharmaceuticals (NASDAQ:AGIO) upgraded to Buy from Hold by JPMorgan. Price target raised to $62 (30% upside) from $50.
    • Quidel (NASDAQ:QDEL) upgraded to Outperform from Market Perform by Raymond James. Price target is $21.50 (20% upside).
    • Aptose Biosciences (NASDAQ:APTO) upgraded to Buy from Neutral by Roth Capital. Price target raised to $8 (186% upside) from $4.
    • Endologix (NASDAQ:ELGX) upgraded to Buy from Hold with a $15.50 (23% upside) price target by Canaccord Genuity.
    • Endo International (NASDAQ:ENDP) upgraded to Neutral from Underperform by Mizuho Securities. Price target raised to $16 (5% downside risk) from $13.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Neutral from Buy by H.C. Wainwright. Price target lowered to $95 (11% downside risk) from $175.
    • Infinity Pharmaceuticals (NASDAQ:INFI) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $1 (32% downside risk) from $11.
    • LDR Holding (NASDAQ:LDRH) downgraded to Market Perform from Outperform by Cowen & Company.
    • Marinus Pharmaceuticals (NASDAQ:MRNS) downgraded to Perform from Outperform by Oppenheimer. $17 price target removed. Also downgraded to Sector Perform from Outperform by RBC Capital.
    • Mesoblast (NASDAQ:MESO) downgraded to Neutral from Outperform by Credit Suisse. Price target lowered to $5 (21% upside) from $10.
    • Revance Therapeutics (NASDAQ:RVNC) downgraded to Hold from Buy by Brean Capital. Price target removed.
    • OraSure (NASDAQ:OSUR) downgraded to Market Perform from Outperform by Raymond James. Price target is $8 (15% upside).
    | Fri, Jun. 17, 7:06 AM | 3 Comments